

MAY 2024

VOLUME 20, Issue 10

Continue learning with EuroIntervention!

With the excitement of EuroPCR now in the past – and it was a wonderful moment to reconnect with colleagues and learn together – we move forward with thoughtful, original research on topics encompassing devices, techniques and, of course, the well-being of our patients.

Short DAPT after NSTEMI-ACS in HBR patients

Davide Cao, Roxana Mehran and colleagues compare the impact of 1 versus 3 months of dual antiplatelet therapy on the clinical outcomes of high bleeding risk patients undergoing percutaneous coronary intervention (PCI) due to non-ST-segment elevation acute coronary syndrome or chronic coronary syndrome. In their findings, a very short duration of dual antiplatelet therapy appears to be a valid bleeding avoidance strategy for these patients.

[See page e630](#)

Early discharge after large-bore CTO PCI

Same-day discharge can augment patient comfort and decrease economic costs, but is this a feasible and safe practice for patients undergoing large-bore chronic total occlusion PCI? **Yvemie B.O. Somsen, Paul Knaapen and colleagues** examine a CTO PCI registry and find that same-day discharge was achieved successfully in over 60% of patients, with low rates of overall vascular access complications.

[See page e643](#)

Impact of calcium morphologies on IVL efficacy

Although calcium modification is recommended before stenting, do different calcium morphologies impact the efficacy of intravascular lithotripsy? **Angela McInerney, Nieves Gonzalo and colleagues** use optical coherence tomography to assess final stent parameters in patients undergoing intravascular lithotripsy for the treatment of calcified coronary artery disease.

[See page e656](#)

Ultrathin-strut versus thin-strut BP-SES: healing and outcomes

Ryutaro Ikegami, Farouc A. Jaffer and colleagues study how the strut thickness of ultrathin-strut versus thin-strut biodegradable-polymer sirolimus-eluting stents impacts vessel healing and clinical outcomes at 30 days and 1 year. Given that the clinical outcomes were similar, they postulate that the benefits of biodegradable-polymer sirolimus-eluting stents may be independent of the strut thickness.

[See page e669](#)